Table 4. Antimicrobial susceptibility (number tested) of Enterobacteriaceae isolates causing bloodstream infection in patients admitted to Mnazi Mmoja Hospital, Zanzibar.
| K. pneumoniae (n = 11) | E. coli (n = 10) | S. Typhi (n = 7) | other Entero-bacteriaceae (n = 8) | Total Entero-bacteriaceae (n = 36)* | Total susceptibility percentage | |
|---|---|---|---|---|---|---|
| Ampicillin | 0** | 6 | 0 | 1 | 7 | 19% |
| Cefotaxime | 6 | 9 | 7 | 7 | 29 | 81% |
| Piperacillin/tazobactam | 7 | 10 | 8 | 25 | 86% | |
| Meropenem | 10*** | 10 | 7 | 8 | 35 | 97% |
| Gentamicin | 8 | 10 | 8 | 26 | 90% | |
| Ciprofloxacin | 10 | 9 | 6 | 8 | 33 | 92% |
| Trimethoprim/sulfamethoxazole | 6 | 3 | 0 | 5 | 14 | 39% |
*for Piperacillin/tazobactam only 29 isolates were analysed. For S. Typhi, the susceptibility to gentamicin was not analyzed: aminoglycosids are not recommended for treatment of S. Typhi infections because they lack activity against intracellular Salmonella[12].
**K. pneumoniae are naturally resistant to ampicillin.
***one intermediate to meropenem, only tested in Zanzibar, cefotaxime, ampicillin, trimethoprim-sulfamethoxazole R, probable ESBL positive.